Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 4/20 | 0.65 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | GAK | O14976 | 1/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4528297 | 0.89 | MAP4K4 (0.49) | MAP4K4DHFRNPC1ALDH1A1MAPK1 | |
| SCHEMBL823753 | 0.88 | MAP4K4 (0.48) | MAP4K4NPC1ALDH1A1MAPK1RAB9A | |
| SCHEMBL4536473 | 0.87 | MAP4K4 (0.49) | MAP4K4NPC1ALDH1A1MAPK1RAB9A | |
| SCHEMBL4122691 | 0.86 | MAP4K4 (0.55) | MAP4K4MPONPC1ALDH1A1MAPK1 | |
| SCHEMBL4529751 | 0.85 | MAP4K4 (0.44) | MAP4K4DHFRNPC1ALDH1A1MAPK1 | |
| SCHEMBL4525197 | 0.85 | ALDH1A1 (0.52) | MAP4K4DHFRNPC1ALDH1A1MAPK1 | |
| SCHEMBL4525204 | 0.84 | MAP4K4 (0.44) | MAP4K4DHFRNPC1ALDH1A1MAPK1 | |
| SCHEMBL4414487 | 0.83 | MAP4K4 (0.45) | MAP4K4DHFR | |
| SCHEMBL4536335 | 0.83 | ADORA2A (0.46) | MAP4K4HRH4NPC1ALDH1A1MAPK1 | |
| SCHEMBL4532151 | 0.83 | MAP4K4 (0.44) | MAP4K4ALDH1A1TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232278-B2 | Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C | GILEAD SCIENCES, INC. (US) | 2012-07-31 | — | — | US | claimed |
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | GILEAD SCIENCES, INC. (US) | 2009-05-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131414-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C | DPYD, TYMP, PNPO | MAP4K4 3289/4885DHFR 13/4885HRH4 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.